NSE filing, NSE: VILINBIO. Summary written from the filing by ALFA Finder's alert engine.
Vilin Bio Med Ltd: key numbers
- Share price
- ₹50.85
- Market cap
- ₹77.55 Cr
- Revenue (annual)
- ₹42.26 Cr
- Net profit (annual)
- ₹1.93 Cr
- P/E (TTM)
- 40.2×Sector 46.1×
- Promoter holding
- 56.65%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vilin Bio Med Ltd
All →Vilin Bio Med Other Announcement
Vilin Bio Med voluntarily filed its Integrated Corporate Governance Report for the quarter ended September 30, 2026, despite being exempt as an NSE Emerge listed entity. No material business transaction or decision is disclosed.
Vilin Bio Med Merger & Restructuring
Vilin Bio Med Limited announced an NCLT-convened meeting on October 15, 2026, to vote on a Scheme of Arrangement with Chemgenix Laboratories Private Limited.
Vilin Bio Med Board Meeting Date
Vilin Bio Med Limited scheduled a board meeting for September 18, 2026, to consider an amalgamation proposal. Trading window remains closed until September 20, 2026.
Vilin Bio Med Acquisition
Vilin Bio Med disclosed NCLT Hyderabad allowed its amalgamation with Chemgenix Laboratories Pvt Ltd. The order directs convening shareholder and creditor meetings for both companies.
Vilin Bio Med Annual General Meeting
Vilin Bio Med Limited conducted its 20th Annual General Meeting on September 2, 2026, to discuss financial statements, director appointments, and related party transactions.
Vilin Bio Med Merger & Restructuring
Vilin Bio Med received a 'No Objection' observation letter from the NSE regarding its merger with Chemgenix Laboratories. The scheme remains subject to further statutory and creditor approvals.
Other acquisition announcements
All →Zensar Technologies Acquisition
Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.
ICICI Lombard General Insurance Company Acquisition Worth ₹172 Cr
ICICI Lombard disclosed that it acquired Rs.172 Crore of State Bank of India shares on October 28, 2026, in its ordinary-course investment function. Its cumulative holding in SBI is now 0.02%.
- Value
- ₹172.0 Cr
- Execution
- Investment made in multiple tranches over a period of time
Emkay Global Financial Services Acquisition Worth ₹30 Cr
Emkay Global will buy Emkay Capital Private Limited for Rs 30 Crore in cash. The related-party deal is expected to complete within 90 days.
- Value
- ₹30.00 Cr
Jindal Stainless Acquisition Worth ₹5.08 Cr
Jindal Stainless acquired an additional ~7% stake in Ampin C&I Three, taking its holding to 24.21%. The cash cost is ~₹5.08 crore for a 40 MW captive solar project.
- Value
- ₹5.08 Cr
- solar captive capacity
- 40.0 MW
OnEMI Technology Solutions Acquisition Worth ₹624.1 Cr
OnEMI Technology's board approved a Rs.624.15 Crore cash investment in Si Creva Capital Services, subscribing 23,37,516 equity shares at Rs.2,670.14 each. Completion is indicated by end-December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Emkay Global Financial Services Acquisition Worth ₹2.05 Cr
Emkay Capital, a subsidiary of Emkay Global, agreed to acquire Emkay Wealth Advisory for Rs. 2.05 Crore cash. The deal is an intra-group restructuring, and the target is a SEBI-registered investment adviser.
- Value
- ₹2.05 Cr
- Execution
- 90 days